MAPKAPK2 and glioma: MAPKAPK2 predicts poor prognosis of glioma patients in the 1p/19q non-codeletion cohort but not in the codeletion cohort, which suggests that MAPAPK2 may assist in the prognosis evaluation of the glioma patients with 1p/19q non-codeletion.